Anpac Bio-Medical Presents 'Cancer Differentiation Analysis' Research at Nobel Laureate Cancer Research Summit

SACRAMENTO, Calif., May 13, 2015 -- Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer and Scientist Dr.Chris Yu this week presented what event organizers published as, "very promising" and "breakthrough" early cancer detection technology research results at the "2015 Nobel Prize Laureate Summit on Biomedical Science: Frontiers in Cancer Research" (NPLS) in Tianjin, China.

The NPLS was the first meeting of five Nobel Laureate Prize winners and the 20 top cancer researchers in the world, gathering for an unprecedented exchange of research results and advances related to cancer identification, diagnosis, and treatment.

An accomplished inventor with over 200 patent applications (100 related to leading-edge cancer research/diagnostics), as well as a member of the American Society of Clinical Oncologists (ASCO), Dr. Yu was welcomed by Summit organizers to share Anpac's innovative "Cancer Differentiation Analysis" (CDA) technology results; revealing Anpac's CDA effectively reinventing cancer screening and early cancer detection, through simple, standard, non-invasive blood tests – known as "Blood Biopsies"-- and Anpac CDA medical devices.

Anpac's CDA technology essentially executes for patients and doctors "Blood Biopsies", which research reveals quickly, efficiently, and dramatically improves cancer detection sensitivity and specificity-- without producing any side effects in patients.

In other words, Anpac's CDA diagnostics can identify threatening cancer cells – and the type of cancer cells (or where they are located in the body) – often before those cells become or grow into Stage 1+ tumors (or potentially even forming into tumors in the first place).

Comprehensive research validity data from nearly 20,000 cases indicate Anpac's CDA diagnostics far exceed existing or competing technologies - revealing a sensitivity and specificity rate range of 70%-85% for over ten different types of cancer, with the ability of early stage detection for most of them.

NPLS organizers list the outline of Dr. Yu's research in the Nobel Prize Laureate Summit Research Paper Compilation as: A New Generation Cancer Diagnostic Technology with High Sensitivity and Specificity, Fast Detection Speed, No Side Effects, Ability for Early Diagnosis, and Cost Efficiency.  And it concludes the research summary with, "CDA technology is a game-changing, effective approach in detecting a number of cancer sites at an early stage with the potential to resolve several existing issues in the field of cancer diagnostics."